Vaxxinity

Biotechnology ResearchFlorida, United States11-50 Employees

Vaxxinity is a U.S.-based biotechnology research company pursuing a new class of medicines to broaden health outcomes. Its core capability is a proprietary platform for synthetic peptide vaccines designed to prevent or treat infectious diseases, including COVID-19, and chronic conditions such as Alzheimer's, Parkinson's, migraine, and hypercholesterolemia. The platform centers on a library of immunosilent UBITh peptides that, when linked to targeted antigens, aim to provoke precise antibody responses with reduced inflammatory risk. The company is headquartered in Dallas, Texas, and lists a Merritt Island, Florida address, underscoring its U.S. footprint.

Vaxxinity operates on a global scale with activities across the United States, Latin America, Europe, and Asia. Its pipeline targets both infectious diseases and chronic disorders, seeking therapies that can have a wide population impact. In 2024, UB-312, a Parkinson's disease candidate, had results published in Nature Medicine indicating reductions in pathological markers and potential clinical benefits. The company sits in the biotechnology research sector as a smaller, globally oriented player pursuing a broad portfolio grounded in peptide-based immunology.

Sign up for free to view info

Email Format Employee directory